Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9)
Author
dc.contributor.author
Westermeier, Francisco
Author
dc.contributor.author
Bustamante, Mario
Author
dc.contributor.author
Pavez, Mario
Author
dc.contributor.author
García Nannig, Lorena
Author
dc.contributor.author
Chiong Lay, Mario
Author
dc.contributor.author
Ocaranza, María Paz
Author
dc.contributor.author
Lavandero González, Sergio
Admission date
dc.date.accessioned
2015-12-29T20:11:00Z
Available date
dc.date.available
2015-12-29T20:11:00Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Pharmacological Research 101 (2015) 41–55
en_US
Identifier
dc.identifier.other
DOI: 10.1016/j.phrs.2015.06.018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/136047
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Insulin-like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9) have been proposed to be important mediators in cardioprotection. A large body of evidence indicates that insulin like growth factor-1 has pleotropic actions in the heart (i.e., contractility, metabolism, hypertrophy, autophagy, senescence and cell death) and, conversely, its deficiency is associated with impaired cardiac function. Recently, we reported that insulin like growth factor-1 receptor is also located in plasma membrane invaginations with perinuclear localization, highlighting the role of nuclear Ca2+ signaling in the heart. In parallel, angiotensin-(1-7) and angiotensin (1-9) acting through Mas receptor and angiotensin type 2 receptor have emerged as a novel anti-hypertensive molecules promoting vasodilatation and preventing heart hypertrophy. In this review we discuss the scientific evidence available regarding insulin-like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9) in cardioprotection and its potential application as novel therapeutic targets for treating cardiac diseases. (c) 2015 Elsevier Ltd. All rights reserved.
en_US
Patrocinador
dc.description.sponsorship
Comision Nacional de Ciencia y Tecnologia (CONICYT), Chile; FONDEF; Anillo; FONDECYT; CONICYT
Ocaranza, María Paz; Palomera, Cristián; Román, Maritza; Bargetto, Jorge; Lavandero González, Sergio; Jalil Milad, Jorge(PERGAMON-ELSEVIER SCIENCE LTD, 2006-02-28)
To determine circulating angiotensin-(1-7) [Ang-(1,7)] levels in rats with different angiotensin converting enzyme (ACE) genotypes and to evaluate the effect of hypertension on levels of this heptapeptide, plasma levels ...
Johnson, M. Cecilia; Castro, Andrea; Troncoso, José Luis; Vantman, David; Devoto, Luigi; Vega Blanco, María Margarita(1998)
Objective: To determine the presence of angiotensin II and angiotensin II type-2 receptor subtype messenger RNA (mRNA) in human fallopian tube. Design: Frozen fallopian tubes were used for all studies. Setting: Procedures ...
BACKGROUND:: Little is known about the biological effects of angiotensin-(1-9), but available evidence shows that angiotensin-(1-9) has beneficial effects in preventing/ameliorating cardiovascular remodeling. OBJECTIVE:: ...